Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06983366

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Assiut University- Faculty of Medicine

Asyut, 71515, Egypt

Location status: Recruiting

Location contact

Ahmad M. Shaddad, MD

CONTACT

[email protected]

+201111171939

Ahmad M. Shaddad, MD

PRINCIPAL_INVESTIGATOR

Aliae A Hussein, MD

PRINCIPAL_INVESTIGATOR

Maiada K Haahem, MD

PRINCIPAL_INVESTIGATOR

About this study

  • The study will enroll adults with various pulmonary pathologies and healthy controls. Lung ultrasound will be performed on all subjects using a standardized 12-zone protocol; each zone will be scored for pleural sliding using the LSI (0-3 per zone; total 0-36). Operator training and calibration will precede enrollment to ensure scoring consistency.
  • A subset of patients will undergo repeat assessments to evaluate intra- and interobserver reliability, using independent, blinded raters.
  • For correlation with LSI, we will collect clinical data, including spirometry, blood gases, symptom scores, and 6-minute walk tests. Diagnostic utility will be evaluated using ROC curves. Satisfaction and feasibility will be assessed via Likert questionnaires, with validation analyses (internal consistency, test-retest reliability).
  • All data will be de-identified and securely stored. Written informed consent will be obtained from all participants.
  • The study groups will include:

1- Pneumothorax 2. Interstitial lung disease (ILD/IPF) 3. COPD/emphysema 4. Bronchiectasis 5. Community-acquired pneumonia 6. Pulmonary edema 7- Pleural effusion 8. Healthy controls

  • Data Collection Methods:
  • Standardized data entry forms for clinical, imaging, and outcome data.
  • Centralized digital storage with access limited to study personnel.

Statistical Methods:

  • Descriptive statistics for baseline data ANOVA or Kruskal-Wallis for group comparisons; post hoc testing as appropriate ROC analysis for diagnostic cut-offs Pearson/Spearman correlation for clinical associations Intraclass correlation coefficients (ICC) for reliability Cronbach's alpha for Likert scale validation Multivariable regression for confounder adjustment

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years and older.
  • Diagnosed with one of the specified pulmonary diseases, or a healthy control
  • Able to provide written informed consent

Exclusion criteria

  • Inability to tolerate or undergo a lung ultrasound
  • Extensive chest wall pathology precluding assessment
  • Unscorable >2 zones per protocol
  • Withdrawal of consent
  • Mechanically-ventilated patients

Treatment and study plan

Lung Ultrasound

Diagnostic Test

All enrolled patient will be subjected to Lung Ultrasound examination LUS

Primary outcomes

  1. Discriminative performance of LSI (total score, 0-36) between disease groups

    Time frame: At Baseline

    The primary outcome is establishing a pattern of LSI among the seven studied groups

Secondary outcomes

  1. Correlation of LSI with clinical severity indices

    Time frame: At Baseline

    Correlation of LSI with clinical severity indices (PaO₂/FiO₂ ratio, FVC %, mMRC, 6MWT)

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmad M. Shaddad, MD

CONTACT

[email protected]

+201111171930

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Collaborators

  • Aliae AR Mohamed Hussein [ahussein

Registry information

Official study title

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases: A Prospective Case-Control Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 21, 2025
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.